Presentation ipre xwebsite
Upcoming SlideShare
Loading in...5
×
 

Presentation ipre xwebsite

on

  • 442 views

 

Statistics

Views

Total Views
442
Views on SlideShare
442
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Presentation ipre xwebsite Presentation ipre xwebsite Presentation Transcript

  • PrEP and interpreting the iPrEx trial results James Wilton Biomedical Science of HIV Prevention Project Coordinator December 6 th , 2010
  • Pre-exposure prophylaxis (PrEP)
  • What is pre-exposure prophylaxis?
    • Breaking it down
    • Pre-exposure = before an exposure
      • Medication used before an exposure occurs
    • Prophylaxis = prevention
      • Medication used for prevention instead of treatment
    • Putting it together
    • Medication used BEFORE an exposure in order to prevent a disease or condition
    • Currently being used
    • Pregnancy (progesterone-based birth control)
    • Malaria (malarone, doxycycline)
    • Tuberculosis (isoniazid)
    • HIV prevention
    •  Antiretrovirals?
  • How would PrEP work?
    • Steps leading to HIV infection
        • An infected body fluid comes into contact with a mucous membrane such as the rectum, vagina, or penis
        • HIV crosses the epithelial barrier and enters underlying tissue
        • Replicates in the mucous membrane tissue (1-3 days)
        • Enters the lymphatic and circulatory system and spreads throughout the body
    • “ Window of opportunity”
      • The time when the amount of virus is small and is replicating at the mucous membrane
      • Antiretrovirals could prevent HIV infection by helping the body clear the virus before it spreads
      • Potential for therapeutic benefit
  • Potential PrEP strategies Route of drug delivery
    • Oral (pill)
    • Topical microbicide(gel)
      • Rectal
      • Vaginal
    • Injection
    • Intravaginal ring
    Dosing schedule
    • Daily
    • Intermittently
    • Coitally (before/sex)
    Number of antiretroviral drugs
    • Single
    • Combination
    Choice of antiretroviral drug
    • Over 25 available
  • What’s being researched?
    • Large-scale studies
    • Oral PrEP
      • Daily pill containing tenofovir (Viread) or tenofovir combined with emtricitabine (Truvada)
    • Topical PrEP
      • 1% tenofovir vaginal gel applied daily or coitally (before/after sex)
    • Smaller Studies
    • Gels used rectally
    • Pills used intermittently or coitally
    • Slow-release intravaginal rings
    • Long-lasting injections
    • Antiretrovirals other than tenofovir and emtricitabine
  • Concerns
    • Partial protection
    • Medical Concerns
      • Safety
      • Drug resistance
    • Behavioral Concerns
      • Adherence
      • Increased risk behavior (risk compensation/disinhibition)
  • CAPRISA 004 Study “ Proof-of-concept” for PrEP
  • CAPRISA Strategy Route of drug delivery
    • Oral (pill)
    • Topical (microbicide)
      • Vaginal Gel
    • Injection
    Dosing schedule
    • Daily
    • Intermittently
    • Coitally
      • Before and after sex
    Number of antiretroviral drugs
    • Single
    • Combination
    Choice of antiretroviral drug
    • Tenofovir
    • Tenofovir + emtricitabine
  • Effectiveness of tenofovir gel
    • Key Points
    • Overall, the HIV incidence was 39% lower among women receiving the tenofovir gel compared to those using a placebo gel
    • Women who used the gel more consistently, both before and after sex, had a greater level of protection against HIV infection
    • The tenofovir gel also reduced the incidence of herpes by 51%
    Effectiveness Overall 39% >80% of sex acts 54% 50-80% of sex acts 38% Less than 50% of sex acts 28%
  • Safety, resistance, and risk behavior
    • No increase in side-effects
      • Mild, self-limiting diarrhea slightly higher in women using the Tenofovir gel
    • No renal toxicity
    • No safety concerns in pregnancy
    • No liver effects in people with Hepatitis B
    • No increase in risk behavior
    • No drug resistance
    • No therapeutic benefit
  • Oral pre-exposure prophylaxis What do we know?
    • Key Points
    • Daily oral tenofovir was generally safe and well tolerated when used by women and men who have sex with men
    • No conclusions could be made on the effectiveness of daily tenofovir
    Study #1 Study #2 Population Heterosexual women (n=~900) Men who have sex with men (n=400) Location(s) Ghana, Nigeria, Cameroon United States Intervention Daily oral tenofovir Daily oral tenofovir Adherence 69% (pill counts) N/A Safety
    • No safety problems
    • No drug resistance
    • No risk compensation
    • Slightly higher frequency of back pain
    • No drug resistance
    • No risk compensation
    # HIV infections 6 (placebo) vs. 2 (daily tenofovir) 3 (placebo) vs. 3 (delayed arm) vs. 0 (daily tenofovir)
  • The Pre-Exposure Prophylaxis Initiative (iPrEx) Study
  • iPrEx Study Basics
    • A Phase III randomized, double-blind, placebo-controlled,
    • safety/efficacy study
    Locations Brazil, Ecuador, Peru, South Africa, Thailand, United States Population Men who have sex with men (n=2499) Study length July 2007 to October 2010 Study groups
    • 1. Daily oral Truvada pill
      • tenofovir (TDF) and emtricitabine (FTC)
    • 2. Daily placebo pill
    Comprehensive package of prevention services
    • HIV testing and risk-reduction counseling
    • Diagnosis and treatment of STIs
    • Condoms
    • Post-exposure prophylaxis
  • iPrEX Strategy Route of drug delivery
    • Oral (pill)
    • Topical (microbicide)
    • Injection
    Dosing schedule
    • Daily
    • Intermittently
    • Coitally
    Number of antiretroviral drugs
    • Single
    • Combination
    Choice of antiretroviral drug
    • Tenofovir
    • Tenofovir + emtricitabine
  • Inclusion/exclusion criteria
    • Inclusion criteria
      • HIV-uninfected men who are 18 years or older
      • High risk for HIV infection (one or more of the following)
        • No condom use during anal intercourse with a male HIV-positive partner or a male partner of unknown HIV status during the last 6 months
        • Anal intercourse with more than 3 male sex partners during the last 6 months
        • Exchange of money, gifts, shelter, or drugs for anal sex with a male partner during the last 6 months
        • Sex with a male partner and STI diagnosis during the last 6 months or at screening
        • Sexual partner of an HIV-infected man with whom condoms are not consistently used in the last 6 months
    • Exclusion criteria
      • Previously diagnosed active or serious infections (ie. Tuberculosis, bone conditions)
      • Active medical problems (ie. heart disease, lung disease, diabetes, cancer)
      • Acute HBV infection or liver cirrhosis
      • Glucose or protein in urine (kidney disorder)
      • History of bone fractures
  • Study participant characteristics
    • Average age was 27 (50% were between 18-24)
    • 1% transgender women
    • Over 70% Hispanic
    • An average of 18 sexual partners in past 12 weeks
    • 40% had transactional sex in past 6 months
    • 60% had unprotected receptive anal intercourse in past 12 weeks
    • 35% infected with HSV-2 (herpes)
  • Study Measures
    • Study visits scheduled every 4 weeks
    • Safety
      • Side-effects
      • Clinical and laboratory adverse events
    • Risk behavior and STIs
    • Adherence
    • HIV status
    • Participants who became HIV-infected
    • CD4 count
    • Viral load
    • Drug resistance
  • Interpreting the results
  • Overall effectiveness of daily Truvada
    • Key Points
    • The HIV incidence in the Truvada group was 44% lower relative to the placebo group
    • The result was statistically significant
    • The overall self-reported adherence was 95%
    • Daily Truvada did not reduce the risk of other STIs
    Truvada Placebo # Study participants 1251 1248 # HIV infections 36 64
  • More effective when taken consistently
    • Key Points
    • Adherence was measured through self-report and pill counts
    • Participants with higher adherence were less likely to become infected
    • Participants had over 90% adherence at 49% of study visits and over 50% adherence at 81% of study visits
    Effectiveness > 90% adherence 73% > 50% adherence 50% < 50% adherence 32%
  • Subanalysis of Truvada group
    • Key Points
    • Many participants did not have drug in their blood despite high self-reported adherence
    • Most participants who became HIV-infected during the trial
    • did not have drug in their blood
    • People with drug in their blood had a 92% lower risk of infection compared to those without drug in their blood
    Participants who remained HIV-negative Participants who became HIV-positive % with drug in their blood 51% 9%
  • Safety of daily Truvada
    • Key Points
    • Daily Truvada was generally safe and well tolerated
    • Elevated serum creatinine levels returned to normal after discontinuing drug
    • Nausea was only higher during the first four weeks
    • Unintentional weight loss may have been due to nausea
    Truvada Placebo Elevated serum creatinine levels 2% 1% Moderate nausea (first 4 weeks) 9% 5% Unintentional weight loss (5% or more) 2.2% 1.1%
  • Risk behavior
    • No evidence of increased risk behavior
      • Total number of sexual partners (in the past 12 weeks) decreased from 12 to 5 partners
      • Use of condoms increased from about 50% to 80%
      • Prevalence of STIs decreased
    • Comprehensive prevention services offered
      • 39,754 visits for HIV counseling and testing
      • 1,019 cases of syphilis were diagnosed and treated
      • 585,000 condoms were distributed
  • Effect of daily Truvada after infection
    • Drug resistance was detected
      • Drug resistance was detected in 2 study participants who started Truvada when they were already HIV-positive
      • No drug resistance was detected in study participants in the Truvada group who became infected during the trial
    • No therapeutic benefit was provided
      • Viral load and CD4 count was similar between those who became infected in the Truvada vs. Placebo group
  • What did the trial tell us?
    • Daily Truvada, in combination with a comprehensive prevention package, reduced HIV incidence among high-risk men who have sex with men.
    • Daily Truvada was more effective when taken consistently
    • The risk of side-effects, toxicity, and drug resistance were low (but this may have been due to poor adherence)
  • What didn’t the trial tell us?
    • Safety/effectiveness of other antiretrovirals
    • The safety and effectiveness of oral Truvada…
      • Over a longer period of time
      • If used only occasionally (intermittently) or coitally
      • In excluded populations (ie. Adolescents and people with underlying health conditions)
      • In preventing against other routes of HIV transmission (ie. intravenous, vaginal/penile)
      • In reducing HIV incidence outside of a clinical trial
    • Risk behavior and adherence under “real life” conditions
    • The “true” risk of drug resistance and side-effects
  • Questions?